Understanding genetic basis for heart disease opens up opportunity for gene editing solution

Understanding genetic basis for heart disease opens up opportunity for gene editing solution

Leaps | 
Later this year, Verve Therapeutics of Cambridge, Ma., will initiate Phase 1 clinical trials to test VERVE-101, a new medication ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists